Hesperos, Inc. Appoints Lawrence Florin as Chief Executive Officer to Lead Company Growth

Hesperos, Inc. Appoints Lawrence Florin as Chief Executive Officer to Lead Company Growth

Nathan Post
Director of Business Operations
npost@hesperosinc.com

Hesperos, Inc., a pioneer in recreating human biology for drug development with its Human-on-a-Chip^® technology, is pleased to announce the appointment of Lawrence (Larry) Florin as Chief Executive Officer. Mr. Florin brings over two decades of leadership experience in the bio / clinical technology arenas, with a proven track record in clinical development, business growth, and strategic innovation.

Prior to joining Hesperos, Mr. Florin served as Chief Clinical Officer at Immunicom, Inc., where he oversaw all immuno-oncology product development efforts. In addition, Mr. Florin continues to serve as a strategic advisor to several biopharma, medtech and clinical research and technology organizations.

"We are thrilled to have Larry lead Hesperos at this pivotal time," said J. Hickman, PhD, Co-founder and Chief Scientist of Hesperos. "His deep expertise in clinical research and his passion for innovation align seamlessly with our mission to accelerate the development of safer, more effective therapeutics."

Throughout his career, Larry has played an integral role in building and growing organizations. He has supported numerous successful fundraising efforts securing more than $120MM, and has been instrumental in the design, implementation and execution of innovative complex clinical trials across a range of therapeutic indications including pediatric and rare diseases. Mr. Florin also has extensive experience with other business development, regulatory and commercial launch positioning activities and strategies, further solidifying his reputation as a life sciences leader. "I am excited to join Hesperos during this period of explosive growth in the emerging MPS field," said Mr. Florin. "With our cutting-edge technology gaining rapid adoption, I’m eager to lead this exceptional team as we continue delivering breakthrough solutions that advance drug discovery and benefit patients globally."

Mr. Florin earned a BS in biology from Ursinus College and an Executive MBA from Temple University. He is a frequent speaker at industry conferences and a recognized leader in leveraging technology to enhance patient recruitment and retention and improve clinical development efficiencies. Under Mr. Florin's leadership, Hesperos is poised to continue its trajectory of growth and innovation, strengthening its position as a pioneer in human-based, preclinical testing models.

About Hesperos, Inc.

Hesperos is a global contract research organization (CRO) specializing in preclinical drug development services through its Human-on-a-Chip^®platform. By replicating key aspects of human biology (and thus avoiding expensive, time-consuming and often less informative animal testing), Human-on-a-Chip^®platform models provide product development teams with more meaningful insights that can accurately predict an agent’s therapeutic profile while lowering costs and accelerating development timelines.

For more information, visit www.hesperosinc.com.